ReGena-Vet Laboratories, LLC

The Best Medicine for Our Best Friends

Tomorrow’s Cures Today

Current Clinical Trials 1:

   Dilated cardiomyopathy in a Doberman Pinscher. In normal myocardium, the section should be nearly all pink from the contractile cardiomyocytes containing with small purple dots (cardiomyocyte nuclei) as in the left panel.  On the right, a section of ventricle from a Dobe with DCM. Note the profound loss of “pink” cardiomyocytes and extensive “white” fibrotic scarring. The loss of contractile heart muscle cells and increased scaring decreases the ability of the heart to contract and causes congestive heart failure.

           We have selected several, currently terminal diseases for testing the efficacy of autologous and allogeneic MSCs. Current investigational diseases include: dilated cardiomyopathy (DCM), degenerative myelopathy (DM), idiopathic pulmonary fibrosis (IPF) and selected heritable metabolic errors (lipoprotein lipase deficiency (LPL-/-), neuronal ceroid lipofuscinosis (NCL) and others. We have started clinical trials in these diseases and anticipate testing additional diseases in the future.

Dilated Cardiomyopathy (DCM):

RECRUIting Doberman PINSCHER Patients ONLY

           This project will investigate the therapeutic potential of adult bone marrow stem cells (MSCs) in treating Doberman pinschers with dilated cardiomyopathy (DCM). We are employing a modified phase I/phase II procedure used by the FDA for new drug evaluation and applying it to stem cells. Following administration of autologous or allogeneic MSCs, we anticipate  the cells migrate to the diseased myocardium, initiate repair and re-growth of cardiomyocytes, as has been reported in experimental laboratory animals. In the last ten years, very encouraging results were obtained using stem cells in laboratory animal models of DCM. Syrian hamsters, which experience a similar